SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer
SINTX Technologies (NASDAQ: SINT) has appointed Gregg R. Honigblum as Chief Strategy Officer (CSO). Honigblum brings over 35 years of experience in healthcare and emerging growth companies, with a background in Wall Street and investment banking. He co-founded Creation Capital and Creation Capital Advisors, and has raised over half a billion dollars throughout his career. Notable achievements include providing early-stage capital for Myriad Genetics and being an early investor in Acacia Biosciences, which was later acquired by Merck for $620 million. In his new role, Honigblum will oversee corporate strategy and enhance investor relations.
SINTX Technologies (NASDAQ: SINT) ha nominato Gregg R. Honigblum come Chief Strategy Officer (CSO). Honigblum porta con sé oltre 35 anni di esperienza nel settore sanitario e nelle aziende in crescita, con un background a Wall Street e nel settore della banchiera d'investimento. È co-fondatore di Creation Capital e Creation Capital Advisors e ha raccolto oltre mezzo miliardo di dollari durante la sua carriera. Tra i suoi successi, si annoverano la fornitura di capitali di avvio per Myriad Genetics e un investimento iniziale in Acacia Biosciences, successivamente acquisita da Merck per 620 milioni di dollari. Nel suo nuovo ruolo, Honigblum supervisionerà la strategia aziendale e migliorerà le relazioni con gli investitori.
SINTX Technologies (NASDAQ: SINT) ha nombrado a Gregg R. Honigblum como Director de Estrategia (CSO). Honigblum aporta más de 35 años de experiencia en el sector de la salud y en empresas de crecimiento emergente, con un historial en Wall Street y banca de inversión. Es cofundador de Creation Capital y Creation Capital Advisors, y ha recaudado más de medio billón de dólares a lo largo de su carrera. Sus logros notables incluyen el suministro de capital inicial para Myriad Genetics y ser un inversionista temprano en Acacia Biosciences, que fue adquirida posteriormente por Merck por 620 millones de dólares. En su nuevo cargo, Honigblum supervisará la estrategia corporativa y mejorará las relaciones con los inversores.
SINTX Technologies (NASDAQ: SINT)는 Gregg R. Honigblum을 최고 전략 책임자(CSO)로 임명했습니다. Honigblum은 헬스케어 및 신생 성장 기업에서 35년 이상의 경험을 가지고 있으며, 월스트리트와 투자은행에서의 배경을 가지고 있습니다. 그는 Creation Capital 및 Creation Capital Advisors를 공동 설립하였고, 경력 동안 5억 달러 이상의 자금을 모집했습니다. 주요 성과로는 Myriad Genetics에 대한 초기 자본 제공과 Merck에 6억 2천만 달러에 인수된 Acacia Biosciences의 초기 투자자가 된 것이 있습니다. 새로운 역할에서 Honigblum은 기업 전략을 감독하고 투자자 관계를 강화할 것입니다.
SINTX Technologies (NASDAQ: SINT) a nommé Gregg R. Honigblum au poste de directeur de la stratégie (CSO). Honigblum apporte plus de 35 ans d'expérience dans le secteur de la santé et les entreprises à forte croissance, avec un parcours à Wall Street et dans la banque d'investissement. Il est co-fondateur de Creation Capital et de Creation Capital Advisors, et a levé plus d'un demi-milliard de dollars tout au long de sa carrière. Parmi ses réalisations notables figurent le financement d'une capitalisation précoce pour Myriad Genetics et un investissement précoce dans Acacia Biosciences, qui a ensuite été acquis par Merck pour 620 millions de dollars. Dans son nouveau rôle, Honigblum supervisera la stratégie d'entreprise et améliorera les relations avec les investisseurs.
SINTX Technologies (NASDAQ: SINT) hat Gregg R. Honigblum zum Chief Strategy Officer (CSO) ernannt. Honigblum bringt über 35 Jahre Erfahrung im Gesundheitswesen und im Bereich aufstrebender Wachstumsunternehmen mit, einschließlich einer Karriere an der Wall Street und im Investment Banking. Er ist Mitbegründer von Creation Capital und Creation Capital Advisors und hat im Laufe seiner Karriere über eine halbe Milliarde Dollar gesammelt. Zu den bemerkenswerten Errungenschaften gehören die Bereitstellung von Frühphasen-Kapital für Myriad Genetics und eine frühe Investition in Acacia Biosciences, das später für 620 Millionen Dollar von Merck übernommen wurde. In seiner neuen Rolle wird Honigblum die Unternehmensstrategie überwachen und die Beziehungen zu Investoren verbessern.
- Appointment of experienced executive with 35+ years in healthcare sector
- New CSO has track record of raising over $500 million for ventures
- Previous success with early-stage investments in companies like Myriad Genetics
- Prior board experience with company's predecessor Amedica
- None.
Seasoned Healthcare Executive to Lead Strategic Growth Initiatives
Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX’s growth initiatives and enhancing investor relations.
Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare sector. His career began on Wall Street as a stockbroker, transitioning into investment banking roles at various firms in New York City. He co-founded Creation Capital LLC and Creation Capital Advisors, investment banking firms with offices in New York and Austin, Texas, focusing on founding and funding breakthrough healthcare technologies.
Throughout his career, Mr. Honigblum has raised over half a billion dollars for various ventures. Notably, Mr. Honigblum was instrumental in providing early-stage capital for Myriad Genetics, the first precision medicine diagnostic company credited with the discovery of BRCA1 and BRCA2 breast cancer genes. Additionally, he was an early-stage investor and financier for Acacia Biosciences, an early informational genomics company that merged with Rosetta Inpharmatics and was subsequently acquired by Merck for
“Gregg’s appointment as Chief Strategy Officer reflects our confidence in his ability to elevate SINTX’s financial and strategic position,” said Eric K. Olson, CEO of SINTX Technologies. “His successful career in emerging technologies and deep investment banking knowledge will be invaluable as we pursue new development opportunities, strengthen investor relationships, and drive our corporate strategy and revenue forward.”
Mr. Honigblum’s deep understanding of the Company’s mission and strategic goals, coupled with his experience as a former member of the board of Amedica, the predecessor of SINTX, positions him to drive the Company’s corporate strategy effectively.
“I am honored to join SINTX at this pivotal juncture,” said Gregg R. Honigblum, Chief Strategy Officer. “The Company’s ongoing development of pioneering technologies in the medical device sector positions it at the forefront of commercialization. I look forward to contributing to the team’s efforts in enhancing shareholder value and drive the Company’s vision forward.”
For more information, please visit www.sintx.com
About SINTX Technologies, Inc.
SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. The Company has manufacturing and R&D facilities in Utah and Maryland. For more information on SINTX Technologies or its materials platform, visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,” "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding advancement of ceramic technologies and exploring new avenues for growth and innovation, and the potential to pursue growth opportunities and explore strategic opportunities.
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX’s other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.
Business and Media Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com
FAQ
Who is the new Chief Strategy Officer of SINTX Technologies (SINT)?
What is Gregg Honigblum's experience before joining SINTX Technologies (SINT)?
What will be Gregg Honigblum's role at SINTX Technologies (SINT)?
What are some notable achievements in Gregg Honigblum's career before SINTX (SINT)?
